» Articles » PMID: 36929285

Bone Marrow Derived Mesenchymal Stem Cells Therapy for Rheumatoid Arthritis - a Concise Review of Past Ten Years

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2023 Mar 17
PMID 36929285
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis is an autoimmune disorder characterized by swelling in synovial joints and erosion of bones. The disease is normally treated with conventional drugs which provide only temporary relief to the symptoms. Over the past few years, mesenchymal stromal cells have become the center of attention for treating this disease due to their immuno-modulatory and anti-inflammatory characteristics. Various studies on treatment of rheumatoid arthritis by using these cells have shown positive outcomes in terms of reduction in the level of pain as well as improvement of the function and structure of joints. Mesenchymal stromal cells can be derived from multiple sources, however, the ones derived from bone marrow are considered most beneficial for treating several disorders including rheumatoid arthritis on account of being safer and more effective. This review summarizes all the preclinical and clinical studies which were conducted over the last ten years for therapy of rheumatoid arthritis utilizing these cells. The literature was reviewed using the terms "mesenchymal stem/stromal cells and rheumatoid arthritis'' and "bone marrow derived mesenchymal stromal cells and therapy of rheumatoid arthritis''. Data was extracted to enable the readers to have access to the most relevant information regarding advancement in therapeutic potential of these stromal cells. Additionally, this review will also help in fulfilling any gap in current knowledge of readers about the outcome of using these cells in animal models, cell line and in patients suffering from rheumatoid arthritis and other autoimmune disorders as well.

Citing Articles

Distinct adaptive immune receptor feature of adipose-derived mesenchymal stem cells (AD-MSCs) treatment of psoriasis.

Tang L, Yao D, He Z, Ye S, Chen X, Huang Y Arch Dermatol Res. 2024; 316(8):542.

PMID: 39162818 DOI: 10.1007/s00403-024-03296-3.

References
1.
Buckner J . Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010; 10(12):849-59. PMC: 3046807. DOI: 10.1038/nri2889. View

2.
Rosenblum M, Remedios K, Abbas A . Mechanisms of human autoimmunity. J Clin Invest. 2015; 125(6):2228-33. PMC: 4518692. DOI: 10.1172/JCI78088. View

3.
Scott D, Wolfe F, Huizinga T . Rheumatoid arthritis. Lancet. 2010; 376(9746):1094-108. DOI: 10.1016/S0140-6736(10)60826-4. View

4.
Ramiro S, Sepriano A, Chatzidionysiou K, Nam J, Smolen J, van der Heijde D . Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76(6):1101-1136. DOI: 10.1136/annrheumdis-2016-210708. View

5.
Ong C, Lirk P, Tan C, Seymour R . An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007; 5(1):19-34. PMC: 1855338. DOI: 10.3121/cmr.2007.698. View